TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15697327

Group type: EXPERIMENTAL
Intervention: Mirtazapine 15-60 mg/day (n = 147)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Fluoxetine 20-40 mg/day (n = 152)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 297
Study: 11319711

Group type: EXPERIMENTAL
Intervention: Bergman minimal model (BMM) with 3-hour IVGTT
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Modified model with delay (MMD) and 5-hour IVGTT
Number of subjects: 8

Group type: COMPARATOR
Intervention: Type 2 diabetes patients (Si)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2-stage euglycemic clamp (Si)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Type 2 diabetes patients (Sg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal nondiabetic subjects using MMD
Number of subjects: 8
Study: 10971979

Group type: EXPERIMENTAL
Intervention: Zuclopenthixol acetate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 50
Study: 7805082

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Warfarin and Aspirin combination
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Low-dose Warfarin
Number of subjects: 1000
Study: 2686257

Group type: EXPERIMENTAL
Intervention: ISDN/ISMN (120 mg/50 mg) + Diltiazem (D)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ISDN/ISMN (120 mg/50 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination therapy with Diltiazem (D)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 4837255

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation + surgery ad modum Wertheim
Number of subjects: 50

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 50
Study: 30786930

Group type: EXPERIMENTAL
Intervention: Structured antenatal pelvic floor muscle exercise (PFME) programme combined with standard antenatal care
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard antenatal care alone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise (PFME)
Number of subjects: 200
Study: 28550895

Group type: EXPERIMENTAL
Intervention: Ultracision
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: MiSeal
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 99
Study: 27844472

Group type: EXPERIMENTAL
Intervention: Tapentadol PR (100-250 mg bid)
Number of subjects: 2968

Group type: COMPARATOR
Intervention: Oxycodone CR (20-50 mg bid)
Number of subjects: 2968

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2968
Study: 24831754

Group type: EXPERIMENTAL
Intervention: Individual drug counseling in addition to buprenorphine-naloxone and medical management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 0
Study: 22540417

Group type: EXPERIMENTAL
Intervention: FertilMate™ Scrotum Cooling Patch for 90 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not wearing patches)
Number of subjects: 40
Study: 19398797

Group type: EXPERIMENTAL
Intervention: Kite method
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ponseti method
Number of subjects: 42
Study: 17135328

Group type: EXPERIMENTAL
Intervention: Advance knowledge of PSA testing (informed consent prior to reporting)
Number of subjects: 210

Group type: COMPARATOR
Intervention: No advance knowledge of PSA testing (informed consent after reporting)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Advance knowledge of PSA testing
Number of subjects: 210

Group type: COMPARATOR
Intervention: No advance knowledge of PSA testing
Number of subjects: 210
Study: 15356066

Group type: EXPERIMENTAL
Intervention: Octreotide (1 microg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Octreotide (1 microg/kg) in GHRP-2-stimulated setting
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Octreotide (1 microg/kg) in GHRH and combined GHRH/GHRP-2-stimulated contexts
Number of subjects: 10
Study: 11421509

Group type: EXPERIMENTAL
Intervention: Formoterol added to budesonide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formoterol added to low dose budesonide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formoterol added to moderate doses of budesonide
Number of subjects: 0
Study: 9678398

Group type: EXPERIMENTAL
Intervention: Community intervention (community organization and public, patient, and health professional education)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (comparison)
Number of subjects: 0
Study: 7733470

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 to 0.75 mg/kg)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Trilene (0.3 to 0.5 vol.%)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Tramal
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Nubain
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Nondrug warming measures
Number of subjects: 116
Study: 2644050

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.2 mg.kg‐1 (Group V)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.15 mg.kg‐1 (Group IV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.1 mg.kg‐1 (Group III)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.05 mg.kg‐1 (Group II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Edrophonium 1.0 mg.kg‐1 (Group I, controls)
Number of subjects: 0
Study: 4911774

Group type: EXPERIMENTAL
Intervention: Vitamin B12 therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 31709970

Group type: EXPERIMENTAL
Intervention: Pearl millet porridge (PMP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Scottish oats porridge (SOP)
Number of subjects: 26
Study: 27898491

Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Number of subjects: 89

Group type: COMPARATOR
Intervention: Intravenous naloxone
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 25659256

Group type: EXPERIMENTAL
Intervention: Autologous PRP (platelet-rich plasma) used in skin transplantation
Number of subjects: 4

Group type: COMPARATOR
Intervention: Standard skin transplantation without PRP
Number of subjects: 4
Study: 23659557

Group type: EXPERIMENTAL
Intervention: EQ‐5D‐3L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EQ‐5D VAS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SF‐6D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SF‐12 new algorithm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All instruments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SF‐6D and SF‐12
Number of subjects: 0
Study: 22050864

Group type: EXPERIMENTAL
Intervention: Blastocyst-stage embryo transfer
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cleavage-stage embryo transfer
Number of subjects: 200
Study: 19276838

Group type: EXPERIMENTAL
Intervention: 12-week multidisciplinary physical activity behavior change intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 41
Study: 17901611

Group type: EXPERIMENTAL
Intervention: P'ASMA (web-based asthma self-management support tool)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Paper-based asthma diary and action-plan
Number of subjects: 21
Study: 15279527

Group type: EXPERIMENTAL
Intervention: Computer-delivered personalized normative feedback intervention
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 252
Study: 11485076

Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus compound (PA Co)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Interferon alpha‐1b (IFN‐alpha 1b)
Number of subjects: 55
Study: 9202362

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study: 2292635

Group type: EXPERIMENTAL
Intervention: Assertion Training (AT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Monthly Assertion Training Boosters (ATB)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Monthly Attention Placebo Boosters (APB)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No Boosters (NB)
Number of subjects: 46
Study: 6108780

Group type: EXPERIMENTAL
Intervention: Metoprolol (ME) 75 mg to 242 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pindolol (PI) 7.5 mg to 23 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Propranolol (PR) 60 mg to 233 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (Isoprenaline)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Metoprolol (ME)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pindolol (PI)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Propranolol (PR)
Number of subjects: 9
Study: 31655603

Group type: EXPERIMENTAL
Intervention: CHO-HG (2.2 g CHO-HG·min-1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CHO-HG
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28343975

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine 2.4 mg/kg weekly
Number of subjects: 415

Group type: COMPARATOR
Intervention: Taxane
Number of subjects: 415
Study: 26430724

Group type: EXPERIMENTAL
Intervention: Rituximab plus fludarabine plus cyclophosphamide
Number of subjects: 329

Group type: COMPARATOR
Intervention: Fludarabine plus cyclophosphamide alone
Number of subjects: 329
Study: 24657236

Group type: EXPERIMENTAL
Intervention: Omalizumab 450 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Omalizumab 525 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Omalizumab 600 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Omalizumab (all doses)
Number of subjects: 32
Study: 22537466

Group type: EXPERIMENTAL
Intervention: Ping Shuai Qigong intervention group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 20668329

Group type: EXPERIMENTAL
Intervention: In house autologous platelet gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vivostat‐ gel
Number of subjects: 100
Study: 18970976

Group type: EXPERIMENTAL
Intervention: BG00012 240 mg three times daily
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 16102623

Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo and aspirin
Number of subjects: 132
Study: 11796288

Group type: EXPERIMENTAL
Intervention: Suspicious DRE findings indicating extracapsular disease
Number of subjects: 2199

Group type: EXPERIMENTAL
Intervention: Suspicious TRUS findings indicating extracapsular disease
Number of subjects: 2199
Study: 9989124

Group type: EXPERIMENTAL
Intervention: Sertraline 50-100 mg per day for 8 weeks
Number of subjects: 768

Group type: COMPARATOR
Intervention: Control group (psychiatric office practice)
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Both groups (primary care and psychiatric office practice)
Number of subjects: 768
Study: 8626939

Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 5711

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5711
Study: 1462277

Group type: EXPERIMENTAL
Intervention: Tenormin (atenolol) 100 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3882061

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg three times a day for two weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31294599

Group type: EXPERIMENTAL
Intervention: parent wise feedback intervention
Number of subjects: 51
Study: 27487786

Group type: EXPERIMENTAL
Intervention: Chang'an I Recipe
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 26561390

Group type: EXPERIMENTAL
Intervention: A/H5N1 vaccine with AS03 adjuvant
Number of subjects: 0
Study: 25060370

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Clopidogrel (both doses)
Number of subjects: 333
Study: 23249323

Group type: EXPERIMENTAL
Intervention: Daytrip tickets for the whole family to a popular amusement park if they returned all postal questionnaires
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: €12.50-worth gift vouchers for sending back the questionnaire on time after each questionnaire round
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Combination of daytrip tickets and gift vouchers
Number of subjects: 771

Group type: COMPARATOR
Intervention: Control group (no incentives)
Number of subjects: 771
Study: 20353117

Group type: EXPERIMENTAL
Intervention: Tuina treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (rest)
Number of subjects: 0
Study: 17545357

Group type: EXPERIMENTAL
Intervention: Removable ankle brace
Number of subjects: 104

Group type: COMPARATOR
Intervention: Below-knee walking cast
Number of subjects: 104
Study: 15723869

Group type: EXPERIMENTAL
Intervention: Standard periodontal therapy (SPT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intensive periodontal therapy (IPT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 65
Study: 12049860

Group type: EXPERIMENTAL
Intervention: 2.5 mg fondaparinux once daily
Number of subjects: 2275

Group type: COMPARATOR
Intervention: 30 mg enoxaparin twice daily
Number of subjects: 2275

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 2275
Study: 9866433

Group type: EXPERIMENTAL
Intervention: Distant Healing (DH) treatment for 10 weeks
Number of subjects: 40
Study: 7839424

Group type: EXPERIMENTAL
Intervention: Cross-match study (CS) patients with detectable lymphocytotoxic antibodies (LA)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Antigen matching study (AMS) patients without detectable LA
Number of subjects: 510

Group type: COMPARATOR
Intervention: Comparison of graft survival between CS and AMS patients
Number of subjects: 510
Study: 2126584

Group type: EXPERIMENTAL
Intervention: High-dose aspirin (100 mg/kg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-dose aspirin (30 mg/kg/day)
Number of subjects: 60
Study: 94871

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 1340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1340
Study: 30924129

Group type: EXPERIMENTAL
Intervention: Graphs with contextual information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Graphs without contextual information
Number of subjects: 0
Study: 31052297

Group type: EXPERIMENTAL
Intervention: Hydrolyzed porcine proteins from blood (HPB)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hydrolyzed porcine proteins from muscle (HPM)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey protein (HW)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hydrolyzed porcine proteins from blood (HPB) and hydrolyzed whey protein (HW)
Number of subjects: 18
Study: 28206788

Group type: EXPERIMENTAL
Intervention: Expectations for antibiotics (Experiment 1)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Expectations for antibiotics (Experiment 2)
Number of subjects: 436
Study: 26323830

Group type: EXPERIMENTAL
Intervention: Value-based cognitive-behavioural therapy (V-CBT) delivered within the first three months after a whiplash injury.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed onset of V-CBT (3 months after randomization).
Number of subjects: 0
Study: 23280604

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: General recreational activities
Number of subjects: 94
Study: 21752247

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Calcium Hydroxide (CH)
Number of subjects: 34
Study: 19857076

Group type: EXPERIMENTAL
Intervention: Daily consumption of jelly containing 0.3 g of S. euboea extract
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo group (daily consumption of the same jelly without the enrichment)
Number of subjects: 51
Study: 17156591

Group type: EXPERIMENTAL
Intervention: 1-hour pamidronate infusion
Number of subjects: 169

Group type: COMPARATOR
Intervention: 2-hour pamidronate infusion
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Multiple myeloma subgroup
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Metastatic breast cancer subgroup
Number of subjects: 169
Study: 15054030

Group type: EXPERIMENTAL
Intervention: Matched randomizations using the signed rank test
Number of subjects: 132

Group type: COMPARATOR
Intervention: Unmatched randomizations using the rank sum test
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Matched randomizations
Number of subjects: 132
Study: 11694775

Group type: EXPERIMENTAL
Intervention: Continuous 24-hour infusion of 5-fluorouracil (5-FU) 2,600 mg/m2 with folinic acid (FA) 500 mg/m2
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard bolus 5-FU/FA with local radiation
Number of subjects: 28
Study: 9366934

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (8.5 +/- 1.5 ml)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (8.3 +/- 1.8 ml)
Number of subjects: 24
Study: 8181207

Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg
Number of subjects: 178

Group type: COMPARATOR
Intervention: Itraconazole 100 mg
Number of subjects: 178
Study: 3111360

Group type: EXPERIMENTAL
Intervention: Ceftazidime 50 mg/kg per dose administered intravenously every 8 h for 14 days
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Ceftazidime 75 mg/kg per dose administered intravenously every 8 h for 14 days
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Ceftazidime (various dosages)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 85
Study: 29168427

Group type: EXPERIMENTAL
Intervention: Neoadjuvant letrozole for 4 months
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Neoadjuvant letrozole
Number of subjects: 119
Study: 27733020

Group type: EXPERIMENTAL
Intervention: Topical oxygen therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care (regular dressings)
Number of subjects: 20
Study: 24729102

Group type: EXPERIMENTAL
Intervention: 600 mg of alpha lipoic acid (ALA) supplementation daily for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo capsules daily for 8 weeks
Number of subjects: 60
Study: 21106264

Group type: EXPERIMENTAL
Intervention: IV N-acetylcysteine plus high-dose hydration with normal saline
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: High-dose hydration with normal saline
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard hydration with normal saline
Number of subjects: 220
Study: 20369525

Group type: EXPERIMENTAL
Intervention: Autograft (group A)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Gamma irradiated allograft (group B)
Number of subjects: 69
Study: 18680998

Group type: EXPERIMENTAL
Intervention: General anesthesia scheme using ketamin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various intensive therapy schemes
Number of subjects: 0
Study: 15768050

Group type: COMPARATOR
Intervention: APC expression levels in leukocytes of relapse patients taking antipsychotic medication
Number of subjects: 89

Group type: COMPARATOR
Intervention: APC expression levels in leukocytes of first-episode drug-naïve patients
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: APC expression levels in leukocytes of healthy controls
Number of subjects: 89

Group type: COMPARATOR
Intervention: Three SNPs (rs2229992, rs42427, rs465899) at the exon region of APC
Number of subjects: 89

Group type: COMPARATOR
Intervention: APC haplotypes from rs2229992-rs42427-rs465899
Number of subjects: 89

Group type: COMPARATOR
Intervention: C-A-T haplotype frequency
Number of subjects: 89
Study: 12465429

Group type: EXPERIMENTAL
Intervention: Tacrolimus + MMF + Steroids (Tac/MMF/S)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Tacrolimus + Azathioprine + Steroids (Tac/Aza/S)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Tacrolimus + MMF (Tac/MMF)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Tacrolimus + Azathioprine (Tac/Aza)
Number of subjects: 489
Study: 10502909

Group type: EXPERIMENTAL
Intervention: Propofol infusion (1 mg.kg‐1.hr‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: No postoperative sedation
Number of subjects: 60
Study: 8746887

Group type: EXPERIMENTAL
Intervention: Treatment group 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment group 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Difference in median survival times between treatment groups
Number of subjects: 0
Study: 1646250

Group type: EXPERIMENTAL
Intervention: Intranasal human calcitonin (hCT) plus sodium glycocholate (SGC)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Intramuscular human calcitonin (hCT) 100 U on alternate days
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intranasal human calcitonin (hCT) 100 U/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Intramuscular human calcitonin (hCT) 100 U/day
Number of subjects: 27
Study: 878552

Group type: EXPERIMENTAL
Intervention: Starr‐Edwards (SEM) prostheses
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lillehei‐Kaster (LKM) prostheses
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bjork‐Shiley (BSM) prostheses
Number of subjects: 50
Study: 30633057

Group type: EXPERIMENTAL
Intervention: Pulsed flow oxygen (2 to 10 L/min for volunteers; 1 to 5 L/min for patients)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Continuous flow oxygen (2 to 10 L/min for volunteers; 1 to 5 L/min for patients)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pulsed flow oxygen (1 to 5 L/min for patients)
Number of subjects: 90

Group type: COMPARATOR
Intervention: ETCO2 measurements without administering oxygen
Number of subjects: 90
Study: 30272234

Group type: EXPERIMENTAL
Intervention: Oral E2 with/without cyclic vaginal progesterone
Number of subjects: 596
Study: 27397522

Group type: EXPERIMENTAL
Intervention: Pregabalin (50 mg every other day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Doxepin (10 mg per day)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Doxepin
Number of subjects: 72
Study: 26431666

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine combined with doxycycline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Doxycycline (control)
Number of subjects: 60